Published in Front Neurosci on September 07, 2010
Role of Mitochondrial Metabolism in the Control of Early Lineage Progression and Aging Phenotypes in Adult Hippocampal Neurogenesis. Neuron (2017) 1.40
The Amyloid Precursor Protein-A Novel Player within the Molecular Array of Presynaptic Nanomachines. Front Synaptic Neurosci (2016) 0.78
Cannabis-induced impairment of learning and memory: effect of different nootropic drugs. EXCLI J (2013) 0.78
Enhanced Neuroplasticity by the Metabolic Enhancer Piracetam Associated with Improved Mitochondrial Dynamics and Altered Permeability Transition Pore Function. Neural Plast (2016) 0.75
Diverse molecular targets for therapeutic strategies in Alzheimer's disease. J Korean Med Sci (2014) 0.75
Effects of ethanolic extract of Fumaria indica L. on rat cognitive dysfunctions. Ayu (2013) 0.75
Genome instability in Alzheimer disease. Mech Ageing Dev (2016) 0.75
Fatty acids rehabilitated long-term neurodegenerative: like symptoms in olfactory bulbectomized rats. J Neural Transm (Vienna) (2014) 0.75
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Mitochondria, oxidants, and aging. Cell (2005) 16.11
Alzheimer's disease is a synaptic failure. Science (2002) 13.82
Alzheimer's disease. N Engl J Med (2010) 13.13
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29
Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol (2000) 4.17
Ageing and neuronal vulnerability. Nat Rev Neurosci (2006) 3.36
Mitochondria in neuroplasticity and neurological disorders. Neuron (2008) 3.35
Mediterranean diet, Alzheimer disease, and vascular mediation. Arch Neurol (2006) 2.98
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
Mediterranean diet and Alzheimer disease mortality. Neurology (2007) 2.45
Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol Aging (2002) 2.06
Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A (2009) 2.04
Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci (2003) 1.81
Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol (2004) 1.66
Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging (2008) 1.59
Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol (2003) 1.55
Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic Biol Med (2005) 1.51
Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J (2007) 1.44
The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem (2009) 1.43
Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res (2009) 1.37
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem (2000) 1.33
Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol Biochem Behav (2004) 1.31
Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem (2004) 1.28
Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal (2007) 1.28
Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord (2008) 1.27
Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr (2005) 1.25
Mitochondria, oxidative stress and aging. Free Radic Res (2000) 1.24
Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) (2008) 1.23
Mitochondrial regulation of neuronal plasticity. Neurochem Res (2006) 1.20
Hope in Alzheimer's fight emerges from unexpected places. Nat Med (2008) 1.20
Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. Mol Neurobiol (2010) 1.17
Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim Biophys Acta (2009) 1.17
Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats. Neurosci Lett (2002) 1.12
Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev (2005) 1.12
Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res (2007) 1.11
Heme, iron, and the mitochondrial decay of ageing. Ageing Res Rev (2004) 1.10
Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic Biol Med (2007) 1.08
Abeta(1-42) reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis. J Neurosci Methods (2008) 1.04
Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease. Neuroscientist (2007) 1.03
Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal (2007) 1.02
Flavonoids and the aging brain. J Physiol Pharmacol (2005) 1.01
Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol (2006) 1.01
Changes of the fluidity of mitochondrial membranes induced by the permeability transition. Biochemistry (1999) 0.95
Piracetam: novelty in a unique mode of action. Pharmacopsychiatry (1999) 0.93
Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement Geriatr Cogn Disord (2002) 0.92
Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol (2006) 0.91
A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons. J Pharmacol Exp Ther (2005) 0.89
Long-term and high-dose piracetam treatment of Alzheimer's disease. Neurology (1993) 0.88
Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J Cereb Blood Flow Metab (1988) 0.88
Plasma amyloid beta protein 42 in non-demented persons aged 75 years: effects of concomitant medication and medial temporal lobe atrophy. Neurobiol Aging (2005) 0.88
Piracetam and dyslexia: effects on reading tests. J Clin Psychopharmacol (1987) 0.87
The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide. Br J Pharmacol (2010) 0.86
Acute reorganization of the forepaw representation in the rat SI cortex after focal cortical injury: neuroprotective effects of piracetam treatment. Eur J Neurosci (1999) 0.86
Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry (1999) 0.86
Mitochondrial permeability transition induced by reactive oxygen species is independent of cholesterol-regulated membrane fluidity. FEBS Lett (2004) 0.84
Systemic administration of catalpol prevents D-galactose induced mitochondrial dysfunction in mice. Neurosci Lett (2010) 0.82
Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. Ann Thorac Surg (2006) 0.82
Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol (1997) 0.82
Influence of the postlesion environment and chronic piracetam treatment on the organization of the somatotopic map in the rat primary somatosensory cortex after focal cortical injury. Neuroscience (2003) 0.82
What is Ginkgo biloba extract EGb 761? An overview--from molecular biology to clinical medicine. Cell Mol Biol (Noisy-le-grand) (2002) 0.82
Natural antioxidants and neurodegenerative diseases. Front Biosci (2004) 0.82
Imaging cortical activity after vestibular lesions. Restor Neurol Neurosci (2010) 0.82
Cerebroprotective effect of piracetam in patients undergoing coronary bypass burgery. Med Sci Monit (2008) 0.81
Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. Int J Clin Pharmacol Ther (1995) 0.81
Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord (1996) 0.81
Plant foods and brain aging: a critical appraisal. Forum Nutr (2006) 0.81
Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Cell Mol Neurobiol (2007) 0.81
Determination of piracetam in rat plasma by LC-MS/MS and its application to pharmacokinetics. Biomed Chromatogr (2010) 0.80
Detection of de- and hyperpolarization of mitochondria of cultured astrocytes and neurons by the cationic fluorescent dye rhodamine 123. J Neurosci Methods (2008) 0.80
Effect of piracetam on cognitive performance in patients undergoing bypass surgery. Pharmacopsychiatry (2003) 0.80
Ginkgo biloba extract EGb 761 protects against mitochondrial aging in the brain and in the liver. Cell Mol Biol (Noisy-le-grand) (2002) 0.80
Towards better brain management: nootropics. Curr Med Chem (2007) 0.80
The action of piracetam on 14C-glucose metabolism in normal and posthypoxic rat cerebral cortex slices. Pol J Pharmacol Pharm (1977) 0.79
Nitric oxide inhibits mitochondrial monoamine oxidase activity and decreases outer mitochondria membrane fluidity. Comp Biochem Physiol C Toxicol Pharmacol (2003) 0.79
Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Alcohol (1996) 0.79
Piracetam-induced changes to membrane physical properties. A combined approach by 31P nuclear magnetic resonance and conformational analysis. Biochem Pharmacol (1995) 0.79
Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. Alcohol (1995) 0.79
Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment. Int Psychogeriatr (1994) 0.79
Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology (1993) 0.78
Piracetam reverses hippocampal membrane alterations in Alzheimer's disease. J Neural Transm (Vienna) (1999) 0.78
Age-related deficits of central muscarinic cholinergic receptor function in the mouse: partial restoration by chronic piracetam treatment. Neurobiol Aging (1992) 0.78
Piracetam activity may differ according to the age of the recipient mouse. Int Pharmacopsychiatry (1980) 0.78
Movement disorders and mitochondrial dysfunction. Curr Opin Neurol (1997) 0.78
Elevated nitric oxide production mediates beta-amyloid-induced mitochondria failure. Pol J Pharmacol (2004) 0.77
Beneficial effect of piracetam monotherapy on post-ischaemic palatal myoclonus. J Int Med Res (2000) 0.76
The effect of piracetam on volunteers in a low-pressure tank. J Int Med Res (1980) 0.76
[Managing vertigo and vertigo syndromes in the elderly]. Presse Med (2001) 0.76
The effectiveness of piracetam in vertigo. Pharmacopsychiatry (1999) 0.76
SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs. Clin Nucl Med (1999) 0.76
Effects of piracetam on developmental dyslexia. Int J Psychophysiol (1986) 0.75
A trial of piracetam in two subgroups of students with dyslexia enrolled in summer tutoring. J Learn Disabil (1991) 0.75
Effect of piracetam administration on 3H-N-methylscopolamine binding in cerebral cortex of young and old rats. Life Sci (1992) 0.75
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study. Brain (2005) 2.51
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke (2003) 2.42
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology (2004) 1.88
Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study. J Am Geriatr Soc (2007) 1.75
Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One (2009) 1.71
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem (2005) 1.64
Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic Biol Med (2005) 1.51
Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis (2008) 1.42
Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci (2004) 1.38
COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann Neurol (2007) 1.34
Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J (2007) 1.31
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol (2006) 1.29
Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem (2004) 1.28
Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal (2007) 1.28
Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol (2003) 1.24
Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) (2008) 1.23
Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord (2004) 1.20
Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. Mol Neurobiol (2010) 1.17
Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PLoS One (2008) 1.17
Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem (2007) 1.16
Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther (2004) 1.16
Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology (2007) 1.16
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol (2002) 1.13
Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal (2012) 1.12
Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res (2007) 1.11
Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis (2009) 1.09
Tocotrienols: constitutional effects in aging and disease. J Nutr (2005) 1.09
Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline. Brain (2014) 1.08
Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease. Mol Neurobiol (2012) 1.07
From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol Neurobiol (2012) 1.07
Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation. J Biol Chem (2008) 1.06
Statins and neuroprotection: a prescription to move the field forward. Ann N Y Acad Sci (2010) 1.05
Increased apoptotic cell death in sporadic and genetic Alzheimer's disease. Ann N Y Acad Sci (2003) 1.04
Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis (2009) 1.04
Age-related impairment of human T lymphocytes' activation: specific differences between CD4(+) and CD8(+) subsets. Mech Ageing Dev (2002) 1.04
Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community. Dement Geriatr Cogn Disord (2007) 1.02
Lipid rafts of purified mouse brain synaptosomes prepared with or without detergent reveal different lipid and protein domains. Brain Res (2003) 1.01
Gender and education impact on brain aging: a general cognitive factor approach. Psychol Aging (2008) 1.01
Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol (2006) 1.01
Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract EGb 761. Ann N Y Acad Sci (2005) 1.00
A new link to mitochondrial impairment in tauopathies. Mol Neurobiol (2012) 1.00
Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Mol Neurobiol (2012) 0.99
Ginkgo biloba extract (EGb761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res (2009) 0.99
Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. Wien Med Wochenschr (2010) 0.99
Isoprenoids, small GTPases and Alzheimer's disease. Biochim Biophys Acta (2010) 0.98
Cholesterol asymmetry in synaptic plasma membranes. J Neurochem (2011) 0.96
Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis (2006) 0.96
Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial. Int Clin Psychopharmacol (2010) 0.96
The amyloid precursor protein protects PC12 cells against endoplasmic reticulum stress-induced apoptosis. J Neurochem (2003) 0.95
Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice. Neurobiol Dis (2005) 0.95
Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim Biophys Acta (2003) 0.94
Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol (2010) 0.93
Cholesterol: Coupling between membrane microenvironment and ABC transporter activity. Biochem Biophys Res Commun (2007) 0.93
Implementation and initial clinical experience of offline PET/CT-based verification of scanned carbon ion treatment. Radiother Oncol (2013) 0.92
Treatment duration (persistence) of basal insulin supported oral therapy (BOT) in Type-2 diabetic patients: comparison of insulin glargine with NPH insulin. Int J Clin Pharmacol Ther (2012) 0.92
Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp Gerontol (2006) 0.91
Gender differences in the prodromal signs of dementia: memory complaint and IADL-restriction. a prospective population-based cohort. J Alzheimers Dis (2011) 0.90
Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology (2006) 0.90
Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing. Biochim Biophys Acta (2010) 0.90
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis. J Neurochem (2014) 0.90
Moderate wine drinkers have lower hypertension-related mortality: a prospective cohort study in French men. Am J Clin Nutr (2004) 0.90
Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One (2013) 0.89
Reduced TRPC channel expression in psoriatic keratinocytes is associated with impaired differentiation and enhanced proliferation. PLoS One (2011) 0.89
Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP). Anal Bioanal Chem (2008) 0.89
Metabolism of boswellic acids in vitro and in vivo. Drug Metab Dispos (2008) 0.89
The amyloid precursor protein potentiates CHOP induction and cell death in response to ER Ca2+ depletion. Biochim Biophys Acta (2006) 0.87
Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol (2010) 0.87
Short- versus long-term prediction of dementia among subjects with low and high educational levels. Alzheimers Dement (2012) 0.87
Generic switch after ramipril patent expiry is not associated with decreased pharmacy refill compliance: a retrospective study using the DAPI database. J Hypertens (2011) 0.87
The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta (2009) 0.86
Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord (2006) 0.85
Executive function deficits in patients with dementia of the Alzheimer's type: a study with a Tower of London task. Arch Clin Neuropsychol (2002) 0.85
Inhibitory breakdown and dementia of the Alzheimer type: a general phenomenon? J Clin Exp Neuropsychol (2002) 0.85
Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord (2009) 0.85
Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochem Int (2013) 0.85
Hydroxytyrosol-rich olive mill wastewater extract protects brain cells in vitro and ex vivo. J Agric Food Chem (2007) 0.84
Hyperforin activates nonselective cation channels (NSCCs). Br J Pharmacol (2005) 0.84
Increased T-cell reactivity and elevated levels of CD8+ memory T-cells in Alzheimer's disease-patients and T-cell hyporeactivity in an Alzheimer's disease-mouse model: implications for immunotherapy. Neuromolecular Med (2007) 0.84
Simvastatin stimulates production of the antiapoptotic protein Bcl-2 via endothelin-1 and NFATc3 in SH-SY5Y cells. Mol Neurobiol (2010) 0.83
Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease. Dement Geriatr Cogn Disord (2007) 0.83
Cardiac oxidative stress and inflammation are similar in SAMP8 and SAMR1 mice and unaltered by curcumin and Ginkgo biloba extract intake. Curr Pharm Biotechnol (2010) 0.82
Monitoring of patients treated with particle therapy using positron-emission-tomography (PET): the MIRANDA study. BMC Cancer (2012) 0.82
Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol (2004) 0.82
Contact lens-induced keratitis resembling central toxic keratopathy syndrome. Cornea (2009) 0.82
Reduction of trophic support enhances apoptosis in PC12 cells expressing Alzheimer's APP mutation and sensitizes cells to staurosporine-induced cell death. J Mol Neurosci (2002) 0.82
TRPC6 channel-mediated neurite outgrowth in PC12 cells and hippocampal neurons involves activation of RAS/MEK/ERK, PI3K, and CAMKIV signaling. J Neurochem (2013) 0.81
Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol Neurobiol (2005) 0.81
Enhancement of proteolytic processing of the beta-amyloid precursor protein by hyperforin. Biochem Pharmacol (2003) 0.80
Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry (2003) 0.80
Plant derived omega-3-fatty acids protect mitochondrial function in the brain. Pharmacol Res (2010) 0.80
Life events and benign paroxysmal positional vertigo: a case-controlled study. Acta Otolaryngol (2006) 0.80
Evidencing inhibitory deficits in Alzheimer's disease through interference effects and shifting disabilities in the Stroop test. Arch Clin Neuropsychol (2004) 0.80
Mitochondrial dysfunction induced by disease relevant AbetaPP and tau protein mutations. J Alzheimers Dis (2006) 0.80
Inter-rater reliability of scales and tests used to measure mild cognitive impairment by general practitioners and psychologists. Curr Med Res Opin (2003) 0.79
Modulation of Pgp function by boswellic acids. Planta Med (2006) 0.79
Expression and functional activity of the bitter taste receptors TAS2R1 and TAS2R38 in human keratinocytes. Skin Pharmacol Physiol (2015) 0.79
Ginkgo biloba extract EGb 761® in the context of current developments in the diagnosis and treatment of age-related cognitive decline and Alzheimer's disease: a research perspective. Int Psychogeriatr (2012) 0.79